TrialBlood2026

CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.

Stephanie Laszig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.